TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Sonova Holding AG (OTC: SONVY) reported stronger-than-expected earnings for fiscal 2025-26, posting normalized EBITA of CHF 811.2 million, above analyst expectations of CHF 780.8 million. The Swiss hearing solutions company also achieved a normalized EBITA margin of 22.5%, outperforming the consensus estimate of 21.6%. Annual sales reached CHF 3.61 billion, matching market forecasts.
The company said foreign exchange headwinds weighed on reported figures, with reported EBITA declining 5.8% year-over-year to CHF 724.2 million. Currency fluctuations reduced normalized EBITA by CHF 106.5 million and cut margins by 1.5 percentage points.
CEO Eric Bernard stated that Sonova delivered results in line with company guidance while continuing to outperform the broader hearing care market. Group sales were nearly flat in Swiss francs but increased 5.9% in local currencies, supported by 5.4% organic growth and additional contributions from acquisitions.
Sonova’s Hearing Instruments division remained the key growth driver. Segment sales climbed 7.5% in local currencies to CHF 3.35 billion, while normalized EBITA rose 20.6% to CHF 793.7 million. The segment achieved a strong 23.7% EBITA margin, highlighting robust demand for hearing aid products.
However, the Cochlear Implants segment faced significant pressure. Sales dropped 11.1% in local currencies to CHF 252.1 million, missing analyst expectations. The company blamed weaker performance in China after the implementation of volume-based procurement measures. Segment EBITA fell sharply to CHF 17.2 million, with margins shrinking to 6.8%.
Sonova also announced that losses tied to its discontinued Consumer Hearing business reached CHF 106.5 million as the company moves forward with plans to divest the unit.
Looking ahead, Sonova forecasts 2026-27 sales growth of 5% to 8% and core EBIT growth of 7% to 10% at constant exchange rates. The board also proposed a record dividend of CHF 4.70 per share, up 7% from last year.
